Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830
Debt
Debt-to-Equity RatioN/A
Current Ratio105.91
Quick Ratio105.91
Price-To-Earnings
Trailing P/E Ratio-12.39
Forward P/E Ratio-13.99
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.83 per share
Price / Book3.80
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees12
Outstanding Shares10,310,000
Market Cap$188.98
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech Inc (NASDAQ:KRYS) announced its quarterly earnings data on Monday, May, 7th. The company reported ($0.21) EPS for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.27. View Krystal Biotech's Earnings History.
What price target have analysts set for KRYS?
3 brokers have issued 1-year price targets for Krystal Biotech's shares. Their predictions range from $35.00 to $38.00. On average, they expect Krystal Biotech's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 99.1% from the stock's current price. View Analyst Ratings for Krystal Biotech.
What is the consensus analysts' recommendation for Krystal Biotech?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Krystal Biotech stock?
Here are some recent quotes from research analysts about Krystal Biotech stock:
- 1. William Blair analysts commented, "Krystal Biotech, Inc. Initi- ating We are initiating coverage of Outperform rating and $29 fair-value estimate. Krystal is developing novel gene therapies for skin dis- eases; lead candidate KB103 is in a Phase I/II trial for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and severe genetic disease affecting the skin and mucosal tissues caused by one or more mutations in the COL7A1 gene, with no currently approved therapies." (7/10/2018)
- 2. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (5/16/2018)
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include Translate Bio (TBIO), CASI Pharmaceuticals (CASI), Mesoblast (MESO), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), Nightstar Therapeutics (NITE), Novavax (NVAX), Vericel (VCEL), PDL BioPharma (PDLI), Scholar Rock (SRRK), Cellular Biomedicine Group (CBMG), Surface Oncology (SURF), Osiris Therapeutics (OSIR) and Adverum Biotechnologies (ADVM).
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 53)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)
- Ms. Pooja Agarwal, VP of Product Devel. (Age 39)
- Mr. Antony A. Riley, Chief Financial Officer (Age 51)
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
Has Krystal Biotech been receiving favorable news coverage?
Media coverage about KRYS stock has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Krystal Biotech earned a media sentiment score of 0.06 on Accern's scale. They also assigned media stories about the company an impact score of 46.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $18.33.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $188.98 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe.
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
